LOGO
LOGO

Corporate News

Synopsys Gains China's Approval To Finalize $35 Bln Ansys Acquisition This Week

By RTTNews Staff Writer   ✉   | Published:   | Follow Us On Google News

Synopsys (SNPS) has received final regulatory approval from China's State Administration for Market Regulation to proceed with its $35 billion acquisition of Ansys.

This approval removes the last major hurdle for the deal, which is expected to close around Thursday.

Chinese regulators approved the transaction with conditions, including that the merged company must maintain existing contracts with Chinese clients. The deal had faced delays amid U.S.-China tensions over technology exports. A resolution came earlier this month when the U.S. eased export rules for chip design and engineering software to China. Regulatory bodies in the U.S. and EU had previously cleared the deal.

Announced in January 2024, the acquisition builds on a seven-year partnership between the two firms. Synopsys CEO Sassine Ghazi previously stated that the merger would create a unified solution from silicon to systems, enhancing innovation for R&D teams across industries.

Under the agreement, Ansys shareholders will receive $197 in cash and 0.3450 shares of Synopsys for each Ansys share. Following the news, Ansys stock rose 4%, nearing its all-time high, while Synopsys shares remained steady and are up 16% year-to-date.

SNPS currently trades at $551.24 or 1.44% lower on the NasdaqGS.

For comments and feedback contact: editorial@rttnews.com

Business News

Global Economics Weekly Update - May 04 – May 08, 2026

May 08, 2026 15:50 ET
Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.

RELATED NEWS
Latest Updates on COVID-19